Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia

被引:23
|
作者
Witjes, WPJ
Rosier, PFWM
deWildt, MJAM
vanIersel, MP
Debruyne, FMJ
delaRosette, JJMCH
机构
[1] Department of Urology, University Hospital Nijmegen, Nijmegen
来源
JOURNAL OF UROLOGY | 1996年 / 155卷 / 04期
关键词
prostate; prostatic hyperplasia; urodynamics; adrenergic alpha receptor blockaders;
D O I
10.1016/S0022-5347(01)66255-4
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We evaluated the urodynamic and clinical effects of terazosin in patients with symptomatic benign prostatic hyperplasia (BPH). Materials and Methods: A total of 45 patients who participated in a multicenter trial was evaluated with urodynamic pressure-flow studies before and after 26 weeks of treatment. Results: Maximum flow rate and symptom score improved significantly in 22 patients with and 11 without bladder outlet obstruction who completed 26 weeks of treatment. In patients with bladder outlet obstruction the condition was significantly reduced and in patients without obstruction, significant urodynamic changes could not be detected. Conclusions: Terazosin treatment results in symptomatic relief and improved urinary flow in patients with and without bladder outlet obstruction, and in significant improvement in patients with urodynamically proved obstruction.
引用
下载
收藏
页码:1317 / 1323
页数:7
相关论文
共 50 条
  • [31] The clinical effects of amitriptyline on nocturia in patients with benign prostatic hyperplasia
    Jeong, H. J.
    Han, D. Y.
    Oh, S. J.
    Park, S. C.
    Rim, J. S.
    Roh, J. H.
    Kim, J. S.
    EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (03) : 170 - 170
  • [32] THE MANAGEMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA WITH THE ONCE-DAILY ALPHA1-BLOCKER, TERAZOSIN
    WOODS, AL
    MILITARY MEDICINE, 1992, 157 (07) : 361 - 364
  • [33] Detrusor collagen in patients with benign prostatic hyperplasia: Interrelationship with urodynamic parameters
    Gomes, CM
    Ribeiro, WO
    Caldini, E
    Battlehner, CN
    Trigo-Rocha, FE
    Freire, GC
    Lucon, AM
    JOURNAL OF UROLOGY, 2005, 173 (04): : 389 - 389
  • [34] Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications
    Lowe, FC
    Olson, PJ
    Padley, RJ
    UROLOGY, 1999, 54 (01) : 81 - 85
  • [35] Tamsulosin Versus Terazosin for Benign Prostatic Hyperplasia: A Systematic Review
    Dong, ZhiLong
    Wang, ZhiPing
    Yang, KeHu
    Liu, YaLi
    Gao, WenHui
    Chen, WenYuan
    SYSTEMS BIOLOGY IN REPRODUCTIVE MEDICINE, 2009, 55 (04) : 129 - 136
  • [36] Terazosin - A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia
    Plosker, GL
    Goa, KL
    PHARMACOECONOMICS, 1997, 11 (02) : 184 - 201
  • [37] Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects
    Wilt, TJ
    Howe, W
    MacDonald, R
    BJU INTERNATIONAL, 2002, 89 (03) : 214 - 225
  • [38] Sexual function in patients with symptomatic benign prostatic hyperplasia.
    Schou, J
    Holm, NR
    Meyhoff, HM
    SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 1996, 30 : 119 - 122
  • [39] Outcome after prostatic artery embolization in patients with symptomatic benign prostatic hyperplasia
    Klow, Nils E.
    Grotta, Ole J.
    Bay, Dag
    Sandbaek, Gunnar
    Johansen, Truls E. Bjerklund
    Hagen, Thijs
    Baco, Eduard
    ACTA RADIOLOGICA, 2019, 60 (09) : 1175 - 1180
  • [40] LONG-TERM EFFICACY AND SAFETY OF TERAZOSIN IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA - COMMENT
    MCCONNELL, JD
    UROLOGY, 1995, 45 (03) : 413 - 413